Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--May 29, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference.
马萨诸塞州列克星敦市--(美通社)--2024年5月29日--Aldeyra Therapeutics股份有限公司（纳斯达克：ALDX）（Aldeyra）是一家处于临床阶段的生物技术公司，致力于开发治疗免疫介导和代谢性疾病的创新疗法，今天宣布，公司总裁兼首席执行官Todd C. Brady博士将在Jefferies Global Healthcare Conference上参加嘉宾演讲。
Dr. Brady's conversation with Kelly Shi, Ph.D., Senior Vice President, Biotechnology Equity Research at Jefferies, is scheduled to begin at 3:30 p.m. ET Wednesday, June 5, 2024. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. Following the fireside chat, the webcast will be archived for 90 days.
Brady博士将与Jefferies生物技术股票研究高级副总裁Kelly Shi博士于2024年6月5日周三下午3:30开始对话。若需观看现场网络直播，请登录Aldeyra网站的投资者与媒体板块:https://ir.aldeyra.com完成嘉宾演讲后，网络直播将保留90天。
About Aldeyra
关于Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the potential treatment of immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.
Aldeyra Therapeutics是一家专注于发现旨在治疗免疫介导和代谢性疾病的创新疗法的生物技术公司。我们的方法是开发调节蛋白质系统的药品，而不是直接抑制或激活单个蛋白靶标，以期在最小化毒性的同时优化多条途径。我们的产品候选包括RASP（活性醛类物质）调节剂ADX-629、ADX-246、ADX-248和与之化学相关的分子，用于潜在治疗免疫介导和代谢性疾病。我们的后期产品候选包括reproxalap，一种RASP调节剂，可潜在治疗干眼病和过敏性结膜炎，以及ADX-2191，一种新型眼内注射甲氨蝶呤制剂，可潜在治疗视网膜色素变性症。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529826900/en/
在businesswire.com上查看原始版本businesswire.com: https://www.businesswire.com/news/home/20240529826900/en/
Investor & Media Contact:
David Burke
Tel: (917) 618-2651
investorrelations@aldeyra.com
投资者及媒体联系方式：
David Burke
电话：(917) 618-2651
investorrelations@aldeyra.com
Source: Aldeyra Therapeutics, Inc.
来源：Aldeyra Therapeutics股份有限公司